<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830371</url>
  </required_header>
  <id_info>
    <org_study_id>EuVCT_TCV301</org_study_id>
    <nct_id>NCT04830371</nct_id>
  </id_info>
  <brief_title>Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants</brief_title>
  <official_title>A Phase II/III, Multicenter, Observer-Blinded, Randomized, Non-inferiority and Safety Study of Typhoid Conjugate Vaccine (EuTCV) Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuBiologics Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuBiologics Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observer-blinded, comparative, single dose, clinical phase II/III study to assess&#xD;
      the immunogenicity and safety of EuTCV compared to Typhoid conjugate vaccine in healthy&#xD;
      Filipino participants aged 6 months to 45 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 18, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>4 weeks after vaccination of EuTCV (pooled of 3 batches)/Typbar-TCV compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Solicited local and systemic AEs</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of unsolicited AEs</measure>
    <time_frame>within 28 days after vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">444</enrollment>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Arm A (Vi-CRM197, Batch #1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #1 will be intramuscularly administered at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (Vi-CRM197, Batch #2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #2 will be intramuscularly administered at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (Vi-CRM197, Batch #3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Typhoid Conjugate Vaccine (Vi-CRM197) Batch #3 will be intramuscularly administered at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (Typbar-TCV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Typhoid Conjugate Vaccine (Typbar-TCV) will be intramuscularly administered at Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EuTCV (Vi-CRM Typhoid conjugate vaccine)</intervention_name>
    <description>Single dose, Intramuscular administration</description>
    <arm_group_label>Arm A (Vi-CRM197, Batch #1)</arm_group_label>
    <arm_group_label>Arm A (Vi-CRM197, Batch #2)</arm_group_label>
    <arm_group_label>Arm A (Vi-CRM197, Batch #3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Typbar-TCV</intervention_name>
    <description>Single dose, Intramuscular administration</description>
    <arm_group_label>Arm D (Typbar-TCV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy participants ≥6 months and ≤45 years of age at enrolment&#xD;
&#xD;
          2. Participants/Parents/Legally Authorized Representative(LAR) willing to give written&#xD;
             informed consent/assent to participate in the trial&#xD;
&#xD;
          3. Participants/Parents/LAR willing to follow the study procedures of the study and&#xD;
             available for the entire duration of the study&#xD;
&#xD;
          4. Participants who are healthy as determined by medical history, with no clinically&#xD;
             significant abnormalities in clinical examination and laboratory tests&#xD;
&#xD;
          5. Female participants must have a negative serum (at Screening) and negative urinary (at&#xD;
             Day 1) pregnancy test and agree to use 2 methods of contraception from dosing until 90&#xD;
             days after vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants/Parents/LAR unwilling to give his/her consent/assent to participate in&#xD;
             the trial&#xD;
&#xD;
          2. Participants concomitantly enrolled or scheduled to be enrolled in another trial&#xD;
&#xD;
          3. Children and infants with a congenital abnormality&#xD;
&#xD;
          4. Known history of immune function disorders including immunodeficiency disease, or&#xD;
             chronic use of systemic steroids, cytotoxic or other immunosuppressive drugs&#xD;
&#xD;
          5. Pregnant, lactating women or women of childbearing age not using a reliable method of&#xD;
             contraception&#xD;
&#xD;
          6. History of uncontrolled coagulopathy or blood disorders&#xD;
&#xD;
          7. Any abnormality or chronic disease which in the opinion of the investigator might be&#xD;
             detrimental for the safety of the participant and interfere with the assessment of the&#xD;
             trial objectives&#xD;
&#xD;
          8. History of alcohol or substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>De La Salle Medical and Health Sciences Institute</name>
      <address>
        <city>Cavite</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the East Ramon Magsaysay Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

